These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24699385)

  • 21. First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.
    McNamara LA; Mbaeyi S
    Lancet Infect Dis; 2021 May; 21(5):586-587. PubMed ID: 33428869
    [No Abstract]   [Full Text] [Related]  

  • 22. Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.
    Granerod J; Davison KL; Ramsay ME; Crowcroft NS
    Epidemiol Infect; 2006 Oct; 134(5):1037-46. PubMed ID: 16492318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross sectional survey of meningococcal C immunisation in children looked after by local authorities and those living at home.
    Hill CM; Mather M; Goddard J
    BMJ; 2003 Feb; 326(7385):364-5. PubMed ID: 12586668
    [No Abstract]   [Full Text] [Related]  

  • 25. Meningococcal carriage: the dilemma of 4CMenB vaccine.
    Taha MK; Deghmane AE
    Lancet; 2014 Dec; 384(9960):2088-90. PubMed ID: 25145776
    [No Abstract]   [Full Text] [Related]  

  • 26. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
    Trotter CL; Ramsay ME; Kaczmarski EB
    Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introducing a new group B meningococcus vaccine.
    Isaacs D; McVernon J
    BMJ; 2014 Apr; 348():g2415. PubMed ID: 24696308
    [No Abstract]   [Full Text] [Related]  

  • 29. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 30. No evidence for political manipulation regarding the new group B meningococcus vaccine.
    Moxon ER; Black S
    BMJ; 2014 May; 348():g2929. PubMed ID: 24812090
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No conspiracy regarding recommendation for a group B meningococcus vaccine.
    Pollard AJ; Riordan A; Ramsay M
    BMJ; 2014 May; 348():g2859. PubMed ID: 24812089
    [No Abstract]   [Full Text] [Related]  

  • 33. [Meningococcal infections. Every case a preventable tragedy].
    Bischoff A
    MMW Fortschr Med; 2008 Jun; 150(24):17. PubMed ID: 18605054
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines.
    Trotter CL; Ramsay ME
    FEMS Microbiol Rev; 2007 Jan; 31(1):101-7. PubMed ID: 17168998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005.
    Can Commun Dis Rep; 2007 Jun; 33(10):1-15. PubMed ID: 17691125
    [No Abstract]   [Full Text] [Related]  

  • 37. Meningococcal group C vaccine and the United Kingdom experience.
    Salisbury D
    Int J Clin Pract Suppl; 2001 Feb; (118):10-1. PubMed ID: 11715358
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].
    Pedersen MØ; Pedersen DS; Pedersen M; Penkowa M
    Ugeskr Laeger; 2008 Feb; 170(6):421-6. PubMed ID: 18252172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy.
    Alfonsi V; D'Ancona F; Giambi C; Nacca G; Rota MC;
    Health Policy; 2011 Dec; 103(2-3):176-83. PubMed ID: 22030308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.